Capsovision Inc (CV) valuation
Capsovision P/E ratio history
Capsovision trades at 2.2 times its earnings over the last twelve months.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $10.69 | -$1.03 | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Capsovision valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| CapsovisionCV | $341M | 2.2 | — | 24.6 |
| Maplight TherapeuticsMPLT | $344M | — | — | — |
| Community Health SystemsCYH | $338M | 8.9 | — | 0.0 |
| Ars PharmaceuticalsSPRY | $336M | — | — | 2.9 |
| Emergent BiosolutionsEBS | $351M | — | 9.7 | 0.5 |
| Atea PharmaceuticalsAVIR | $329M | — | — | — |
| Fennec PharmaceuticalsFENC | $356M | — | 16.2 | 6.0 |
| Clearpoint NeuroCLPT | $325M | — | — | 7.1 |
| Quantum SiQSI | $318M | — | — | 198.1 |
| Peer median | 8.9 | 12.9 | 4.4 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: CV financials · CV returns
No forecast, no recommendation. This page describes Capsovision Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.